NEOG · XBRL financial data

Neogen financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (NEOG's year ends in late May)

In millions of dollars	Q2 FY24Nov 30, 2023	Q3 FY24Feb 29, 2024	Q4 FY24May 31, 2024	Q1 FY24Aug 31, 2024	Q2 FY25Nov 30, 2024	Q3 FY25Feb 28, 2025	Q4 FY25May 31, 2025	Q1 FY26Aug 31, 2025	Q2 FY26Nov 30, 2025	Q3 FY26Feb 28, 2026	Q4 FY26May 31, 2026	Q1 FY27Aug 31, 2026
Revenue from contracts with customers	230	229	237*	217	231	221	225*	209	225	211	225*	223
Cost of revenue	—	—	year only	—	—	—	year only	—	—	—	—	—
Cost of goods and services sold	113	112	123*	112	118	111	133*	114	118	112	118*	117
Gross profit	117	117	113*	105	113	110	93*	95	107	99	108*	106
Research and development	6	5	5*	5	5	4	6*	5	5	4	5*	7
General and administrative	52	52	51*	52	58	56	53*	61	65	60	59*	59
Total operating expenses	102	105	100*	103	571	105	704*	111	112	102	105*	107
Operating income (loss)	14	12	13*	2	(457)	5	(611)*	(16)	(5)	(3)	3*	(2)
Interest expense	10	10	11*	—	—	—	year only	—	—	—	year only	—
Other income (expense)	(2)	(1)	(2)*	(0)	(2)	2	(4)*	(1)	(1)	(3)	(1)*	1
Income tax expense (benefit)	(0)	(4)	(1)*	(3)	(20)	1	(19)*	7	(4)	(3)	(1)*	(3)
Net income (loss)	(3)	(2)	(5)*	(13)	(456)	(11)	(612)*	36	(16)	(17)	(11)*	(12)
Earnings per share, basic USD per share	(0.02)	(0.01)	(0.02)*	(0.06)	(2.10)	(0.05)	(2.82)*	0.17	(0.07)	(0.08)	(0.05)*	(0.05)
Earnings per share, diluted USD per share	(0.02)	(0.01)	(0.03)*	(0.06)	(2.10)	(0.05)	(2.82)*	0.17	(0.07)	(0.08)	(0.05)*	(0.05)
Weighted average shares, basic millions of shares	216	217	217*	217	217	217	217*	217	217	218	218*	218
Weighted average shares, diluted millions of shares	216	217	216*	217	217	217	217*	217	217	218	218*	218

Balance sheet

CSV

Fiscal quarters (NEOG's year ends in late May)

In millions of dollars	Q2 FY24Nov 30, 2023	Q3 FY24Feb 29, 2024	Q4 FY24May 31, 2024	Q1 FY24Aug 31, 2024	Q2 FY25Nov 30, 2024	Q3 FY25Feb 28, 2025	Q4 FY25May 31, 2025	Q1 FY26Aug 31, 2025	Q2 FY26Nov 30, 2025	Q3 FY26Feb 28, 2026	Q4 FY26May 31, 2026	Q1 FY27Aug 31, 2026
Cash and cash equivalents	206	161	171	120	140	128	129	139	145	160	186	172
Marketable securities	25	7	0	0	0	0	0	—	—	—	—	—
Accounts receivable	150	174	173	168	164	160	153	138	132	137	147	136
Inventory	161	182	189	199	198	205	191	193	163	162	144	146
Prepaid and other current assets	83	78	56	54	68	58	53	53	58	63	60	58
Total current assets	624	602	589	541	570	552	577	524	575	590	605	583
Property and equipment, net	244	272	277	301	311	328	339	346	332	332	330	330
Right-of-use asset	15	15	15	14	17	17	17	17	15	16	17	19
Goodwill	2,138	2,136	2,136	2,137	1,673	1,672	1,065	1,066	1,046	1,048	1,047	1,048
Total assets	4,602	4,582	4,549	4,503	4,054	4,036	3,444	3,378	3,360	3,359	3,346	3,303
Accounts payable	112	90	83	61	80	72	80	77	63	75	79	78
Current portion of long-term debt	3	3	2	—	—	—	19	—	—	—	0	—
Total current liabilities	177	158	154	123	151	141	174	146	147	151	158	150
Long-term debt	887	888	888	889	890	891	875	793	793	793	794	774
Lease liability, non-current	—	—	10	—	—	—	13	—	—	—	14	—
Total liabilities	1,455	1,436	1,405	1,368	1,385	1,376	1,373	1,260	1,255	1,257	1,253	1,217
Retained earnings (accumulated deficit)	563	561	556	543	87	76	(536)	(500)	(516)	(533)	(544)	(556)
Total stockholders' equity	3,148	3,146	3,144	3,135	2,669	2,660	2,071	2,119	2,104	2,102	2,093	2,086
Total liabilities and equity	4,602	4,582	4,549	4,503	4,054	4,036	3,444	3,378	3,360	3,359	3,346	3,303
Common shares outstanding (cover page) millions of shares	217	217	217	217	217	217	217	217	218	218	218	218

Cash flows

CSV

Fiscal quarters (NEOG's year ends in late May)

In millions of dollars	Q2 FY24Nov 30, 2023	Q3 FY24Feb 29, 2024	Q4 FY24May 31, 2024	Q1 FY24Aug 31, 2024	Q2 FY25Nov 30, 2024	Q3 FY25Feb 28, 2025	Q4 FY25May 31, 2025	Q1 FY26Aug 31, 2025	Q2 FY26Nov 30, 2025	Q3 FY26Feb 28, 2026	Q4 FY26May 31, 2026	Q1 FY27Aug 31, 2026
Net income (loss)	(3)	(2)	(5)*	(13)	(456)	(11)	(612)*	36	(16)	(17)	(11)*	(12)
Stock-based compensation	4*	4*	4*	4	5*	4*	4*	5	4*	1*	3*	3
Depreciation and amortization	29*	30*	29*	30	30*	29*	30*	29	29*	29*	29*	29
Net cash from operating activities	16*	(30)*	27*	(18)	40*	19*	17*	11	19*	23*	30*	13
Net cash from investing activities	12*	(15)*	(18)*	(34)	(17)*	(32)*	(16)*	98	(12)*	(12)*	(4)*	(8)
Proceeds from long-term debt	—	—	year only	—	—	—	year only	—	—	—	year only	—
Repayments of long-term debt	—	0*	0*	0	(0)*	0*	550*	100	0*	0*	0*	20
Net cash from financing activities	(0)*	1*	(0)*	1	(1)*	1*	(2)*	(99)	(0)*	1*	(0)*	(19)
Net change in cash	27*	(44)*	9*	(50)	20*	(13)*	1*	10	6*	15*	26*	(14)

Compare with peers

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Neogen	172	223	13	218.3M	—	Q1 FY27 10-QAug 31, 2026
Akebia Therapeutics	156	49	3.5*	277.1M	—	Q2 FY26 10-QJun 30, 2026
Aurinia Pharmaceuticals	46	84	46*	134.0M	—	Q3 FY26 10-QSep 30, 2026
Viridian Therapeutics	165	not reported	(105)*	113.3M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
Harrow	84	71	(9.8)*	37.5M	8.6 quarters	Q2 FY26 10-QJun 30, 2026
Novavax	191	57	(73)*	164.9M	9.9 quarters	Q2 FY26 10-QJun 30, 2026
Collegium Pharmaceutical	129	200	71*	32.6M	—	Q2 FY26 10-QJun 30, 2026
Ardelyx	46	128	2.2*	251.4M	—	Q3 FY26 10-QSep 30, 2026
CorMedix	257	102	86*	77.9M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.